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Abstract
Background: Although the effectiveness of radiotherapy with concurrent administration of several anti-
tumor drugs for postoperative recurrent esophageal cancer has been demonstrated, the results are not
satisfactory. The purpose of the present study was to evaluate the effectiveness and safety of radiotherapy
combined with nedaplatin and 5-FU for postoperative locoregional (excluding hematogenous metastasis)
recurrent esophageal cancer.
Methods: In June 2000, we started a phase II study on treatment of postoperative locoregional recurrent
esophageal cancer with radiotherapy (60 Gy/30 fr/6 weeks) combined with chemotherapy consisting of
two cycles of nedaplatin (70 mg/m2/2 h) and 5-FU (500 mg/m2/24 h for 5 days).
The primary endpoint of the present study was overall survival rate, and the second endpoints were
irradiated-field control rate, tumor response and toxicity.
Results: A total of 30 patients were included in this study. The 1-year and 3-year overall survival rates
were 60.6% and 56.3%, respectively, with a median survival period of 39.0 months, and the 1-year and 3-
year irradiated-field control rates were 86.4% and 72%, respectively. Complete response and partial
response were observed in 13.3% and 60.0% of the patients, respectively. Grade 3 or higher
leukocytopenia and thrombocytopenia were observed in 30% and 3.3% of the patients, respectively, but
renal toxicity of grade 3 or higher was not observed. The regimen was completed in 76.7% of the patients.
In univariate analysis, the difference between survival rate in preradiotherapy performance status,
recurrent pattern (worse for patients with anastomotic recurrence) and age (worse for younger patients)
were statistically significant.
Conclusion: Radiotherapy combined with nedaplatin and 5-FU is a safe and effective salvage treatment
for postoperative locoregional recurrent esophageal cancer.
Published: 04 March 2006
BMC Cancer2006, 6:50 doi:10.1186/1471-2407-6-50
Received: 01 November 2005
Accepted: 04 March 2006
This article is available from: http://www.biomedcentral.com/1471-2407/6/50
© 2006Jingu et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Cancer 2006, 6:50 http://www.biomedcentral.com/1471-2407/6/50
Page 2 of 9
(page number not for citation purposes)
Background
Since the mid-1980's, extended radical esophagectomy
with three-field (neck, mediastinum, and abdomen)
lymph node dissection has been performed, and it seems
to have improved survival of patients with esophageal
cancer [1-3]. However, there is recurrence in 27~52% of
operated patients and locoregional recurrence in
41.5~55% of patients with postoperative recurrence [3-9].
Although the effectiveness of radiotherapy and concurrent
chemoradiotherapy using cisplatin (CDDP) + 5-fluorour-
acil (5-FU) or a combination of several anti-tumor drugs
for postoperative recurrent esophageal cancer has been
demonstrated, median survival periods have been only
7.0~11.0 months [9-19]. These results are not satisfactory.
Nedaplatin (Cis-Diammine-Glycoplatinum:CDGP), a
derivate of CDDP that shows anti-tumor activity similar
to that of CDDP and has less renal and gastrointestinal
toxicity [20-23], is now being used clinically to treat can-
cer patients in Japan. The chemical structures of CDGP
and CDDP are shown in Fig. 1. The rate of response to
CDGP alone for treatment of esophageal cancer was
reported to be 51.7% (15 partial responses obtained in 29
patients) [21]. CDGP + 5-FU seemed to have a superior
effect to that of CDDP + 5-FU in a preclinical study [22]
and has been shown to be safe and effective for treatment
of esophageal cancer in some clinical studies
[16,17,24,25].
Based on these facts, we started a phase study II on the
effectiveness of radiotherapy combined with CDGP and
5-FU for postoperative locoregional recurrence of esopha-
geal cancer.
Methods
In June 2000, we started the present study in three insti-
tutes, Tohoku University Hospital and two affiliated hos-
pitals, according to the following protocol.
All patients had histologically proven squamous cell car-
cinoma of the esophagus. Patient selection criteria
included 1) 30 to 80 years of age, 2) Eastern Cooperative
Oncology Group (ECOG) performance status of 0 to 3, 3)
no other active cancer, 4) no serious cardiac, liver, or pul-
monary disease, 5) creatinine clearance of more than 50
ml/min, 6) adequate bone marrow function (leukocyte
count of 4000/µl, platelet count of 100,000/µl, 7) locore-
gional recurrence (including para-aortic lymph node
metastasis) without distant metastasis after no residual
tumor (R0) resection; extended radical esophagectomy
with three-field (neck, mediastinum, and abdomen)
lymph node dissection, and 8) no previous therapy other
than R0 resection.
Recurrence was diagnosed comprehensively by upper gas-
trointestinal endoscopy, ultrasonography, computed
tomography (CT), physical findings and/or cytology.
A linear accelerator (4 MV or 10 MV) was used as the X-ray
source. The target volume was localized for radiotherapy
in all patients by CT planning. The daily fractional dose of
radiotherapy was 2.0 Gy, administered 5 days a week, and
the total dose was 60.0 Gy. For 11 patients who had
metastasis of lymph nodes in some regions or metastasis
of many lymph nodes in one region, a T-shaped field
(including the bilateral supraclavicular, mediastinal and
abdominal regions) was used. For the remaining 19
patients, local fields with a margin of 1 to 2 cm from the
macroscopic tumor were used. After a total dose of 40 Gy,
the field was changed for all patients to avoid the spinal
cord, and only macroscopic lesions were irradiated with a
margin of 1 to 1.5 cm. To decrease the incidence of radia-
tion pneumonitis, we avoided as much as possible irradi-
Schedule of the protocol of chemoradiotherapy Figure 2
Schedule of the protocol of chemoradiotherapy.
Chemical structures of cisplatin and nedaplatin Figure 1
Chemical structures of cisplatin and nedaplatin.BMC Cancer 2006, 6:50 http://www.biomedcentral.com/1471-2407/6/50
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ating more than 30% of V20, which is the percentage of the
total lung volume that received > 20 Gy.
Each cycle of chemotherapy consisted of 120-minute infu-
sion of CDGP at 70 mg/m2 and a 5-day period of 5-FU at
500 mg/m2/day. The median doses per body of CDGP
and 5-FU were 100 mg/day (range, 80 to 125 mg/day) and
750 mg/day (range, 500 to 900 mg/day), respectively.
This cycle of chemotherapy was repeated with an interval
of 3 or 4 weeks, for a total radiotherapy dose of 60 Gy (Fig.
2). However, if toxicity of grade 3 or higher was noted and
prolonged, we suspended or discontinued chemotherapy
or reduced the dose of CDGP alone or the dose of both
CDGP and 5-FU by 25~30% in the subsequent cycle.
Completion of the regimen in this study was defined as
completion of two cycles of full-dose CDGP + 5-FU for a
total radiotherapy dose of 60 Gy without suspension of
treatment.
The overall survival, relapse-free survival and irradiated-
field control rates were calculated from the first date of
radiotherapy.
The primary endpoint of the current study was overall sur-
vival rate, and the second endpoints were tumor response,
relapse-free survival rate, irradiated-field control rate and
toxicity.
RECIST (Response Evaluation Criteria in Solid Tumors)
was used to determine the tumor response. Tumor
response was evaluated by CT 1~2 months after chemora-
diotherapy. The number of mean measurable lesions was
1.8 per patient, and the response was evaluated according
to agreement of more than two radiation-oncologists. In
the present study, metastasis of para-aortic lymph nodes
was defined as regional recurrence.
Follow-up evaluations were performed every 3~6 months
for the first 2 years and every 12 months thereafter by
endoscopy and CT.
We defined what only progression disease (PD) according
was the failure of the present regimen (relapse again).
Survival estimates were calculated using the Kaplan-Meier
method, and differences were evaluated by the log-rank
Table 1: Patient characteristics
Patients
Age years old
median 64
range 50–72
Gender Number of patients
male 29
female 1
Preoperative Stage (UICC* 1997) Number of patients
I4
II A 2
II B 3
III 17
IV 2
unknown 2
Site of recurence Number of patients
supraclavicular lymph node 9
mediastinal lymph node 14
abdominal lymph node 7
local 9
Performance Status (ECOG†) Number of patients
01 0
11 5
23
32
40
State at last observation date (August 31, 2005) Number of patients
alive 15
dead 13
unknown 2
* UICC: Union Internationale Contre le Cancer, † ECOG: Eastern Cooperative Oncology GroupBMC Cancer 2006, 6:50 http://www.biomedcentral.com/1471-2407/6/50
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test. Cox's proportional hazards regression model was
used for univariate survival analysis. Age, preoperative
stage (I – II vs. III – IV: Union International Contre le Can-
cer 1997 (UICC1997)), time interval between surgery and
recurrence, pre-radiotherapy performance status (0–1 vs.
2–3), radiation field (local alone vs. T-shaped), acute
tumor response (complete regression (CR) ~ partial
regression (PR) vs. stable disease (SD) ~ PD), relapse
again inside the irradiated field (yes vs. not), number of
cycles of chemotherapy (one vs. two), recurrent pattern
(anastomotic vs. non-anastomotic) and number of recur-
rent regions (one region vs. multiple regions) were
entered into univariate analysis. In univariate analysis, age
and time interval between surgery and recurrence were
not classified in categories. A p value of less than 0.05 was
considered significant. All analyses were performed using
SPSS 11.0.
Toxicity was graded according to the Common Terminol-
ogy Criteria for Adverse Events (CTCAE v3.0).
The present study protocol was reviewed and approved by
the Tohoku University Hospital Institutional review
board, and informed consent was obtained from each
patient before conducting the treatment.
Results
From June 2000 to December 2004, a total of 30 patients
(29 males, 1 female; median age, 64 years; age range, 50
to 72 years) were enrolled in this phase II study. Patient
characteristics are shown in Table 1. The sites of recur-
rence were supraclavicular lymph nodes (9 patients),
mediastinal lymph nodes (14 patients), abdominal
(including para-aortic) lymph nodes (7 patients) and
anastomotic recurrence (9 patients). Five patients had
recurrence or metastatsis in two regions and 2 patients
had recurrence in three regions. The median time interval
from surgery to recurrence was 12.5 months (range, 4 to
102 months). The median period of the regimen in the
present study was 42 days (range, 37 to 106 days).
Although all of the patients except for one patient who
had a 59-day idle period because of acute cholecystitis
completed the regimen of radiotherapy without suspen-
sion of treatment, 7 patients did not complete the regi-
men of chemotherapy because of adverse events in the
acute phase (The second cycle of chemotherapy was can-
celled in 5 patients, and the dose of CDGP alone or the
dose of both CDGP and 5-FU were reduced in 2 patients.).
The rate of completion of this regimen was 76.7%.
The last observation date was August 31, 2005. The
median follow-up period was 12.5 months (range, 4.0 to
62.0 months) for all patients and 18.0 months (range, 4.5
to 62.0 months) for patients still alive. Sixteen of the 30
patients had relapse again. Thirteen patients out of a total
of 30 died; 10 patients due to progression disease, 2
patients due to intercurrent diseases and one patient due
to iatrogenic cause. At the last observation date, 15
patients remained alive, and 2 patients were lost to follow
up.
The 1-year and 3-year overall survival rates were 60.6%
(95%CI = 42.4–78.8) and 56.3% (95%CI = 37.5–75.1),
respectively, with a median survival period of 39.0
months (95% CI = 0.0–82.3) (Fig. 3). Overall response
rate, including complete responses in 4 patients and par-
tial responses in 18 patients, was 73.3% (Table 2). There
was not correlation between tumor response and site of
recurrence or between overall survival rate and site of
recurrence.
The 1-year and 3-year relapse-free survival rates were
53.4% and 35.6%, respectively, and the 1-year and 3-year
irradiated-field control rates were 86.4% and 72%, respec-
tively (Fig. 4).
As the major toxicity in the acute phase, grade 3 leukocy-
topenia was observed in 9 (30%) of the patients. How-
ever, grade 4 leukocytopenia was not observed in any of
Table 2: Treatment response (RECIST: Response Evaluation 
Criteria in Solid Tumors)
Treatment response No.
CR* 4
PR§ 18
SD† 7
PD# 1
CR: complete response, §PR: partial response, † SD: stable disease, 
#PD: progression disease
Overall survival of patients with postoperative locoregional  recurrent esophageal cancer/(Kaplan-Meier method) Figure 3
Overall survival of patients with postoperative locoregional 
recurrent esophageal cancer/(Kaplan-Meier method).BMC Cancer 2006, 6:50 http://www.biomedcentral.com/1471-2407/6/50
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the patients. Thrombocytopenia of grade 3 or higher was
observed in one patient, diarrhea of grade 3 or higher was
observed in two patients, and heartburn or mucositis of
grade 3 or higher was observed in one patient. These grade
3 hemotoxicities were controllable and transitory, and
some patients with grade 3 hemotoxicity were therefore
able to complete the regimen without suspension of treat-
ment or reduction of dose in the second cycle of chemo-
therapy. Grade 1 renal toxicity was observed in one
patient, but no patient had renal toxicity of grade 2 or
higher. These toxicities were manageable and there was no
fatal (grade 5) toxicity in the acute phase (Table 4). How-
ever, one patient died 6 months after the protocol due to
serious pericardial effusion. There were no patients often
than the patient who had grade 3 or higher toxicities in
the late phase, although grade 1 or 2 focal pulmonary
fibrous change, pericardial effusion and/or pleural effu-
sion were often observed. There was a strong correlation
between radiation field (T-shaped or local alone) and
acute adverse events (<grade 3 or >grade 3), rate of occur-
rence of grade 3 or higher adverse events being signifi-
cantly higher in patients who underwent radiotherapy
with a T-shaped field (p = 0.046; Pearson's product
moment correlation coefficient = -0.367).
In univariate analysis, the difference between survival rate
in performance status (p = 0.033, Exp (B) = 4.599, 95%CI
= 1.131–18.696), age (p = 0.034, Exp (B) = 0.909, 95%CI
= 0.833–0.993) and recurrent pattern (p = 0.024, EXP (B)
= 0.261, 95%CI = 0.081–0.836) were statistically signifi-
cant (Table 5).
Discussion
There have been some studies on the effectiveness of radi-
otherapy (with or without chemotherapy) for treatment
of postoperative recurrent esophageal cancer. In those
studies, the median survival periods were 7.0~9.5 months
and the 1-year survival rates were 28~69% (Table 3) [12-
16,25]. The median survival periods in previous studies
on the effectiveness of chemotherapy alone for treatment
of recurrent esophageal cancer were similar, 5.0~10.5
months [10,17-19]. None of the results were good. In
2001, we also reported the results of a study on the effec-
tiveness of radiotherapy (with or without concurrent
chemotherapy) for treatment of postoperative locore-
gional recurrent esophageal cancer: the median survival
period of patients who did not undergo chemotherapy
was 7.0 months, the median survival period of patients
who underwent chemotherapy (CDDP and 5-FU) was 9.0
months, and the overall 1-year and 3-year survival rates
were 33 and 15%, respectively [15]. In 2003, we reported
the results of a study on the effectiveness of radiotherapy
combined with CDGP + 5-FU in our institution for treat-
ment of 7 patients with postoperative locoregional recur-
rent esophageal cancer: the 1-year survival rate was 69%
(The median survival period could not be calculated.)
[16]. Compared with these results, the results of the
present study showing overall median survival period of
39.0 months and 1-year survival rate of 60.6% were excel-
Table 4: Major toxicities related to this regimen (the Common Terminology Criteria for Adverse Events: CTCAE v3.0)
Toxicity Grade 1 Grade 2 Grade 3 Grade 4 Grade 5
neutropenia 16.7% 33.3% 30% 0% 0%
thrombocytopenia 3.3% 0% 0% 3.3% 0%
heartburn or 
mucositis
50% 3.3% 3.3% 0% 0%
renal toxicity 3.3% 0% 0% 0% 0%
diarrhea 16.7% 20% 3.3% 3.3% 0%
Table 3: Contents and results of radiotherapy (with or without chemotherapy) for postoperative recurrent esophageal cancer. in 
previous studies. The numbers in parenthesis are a numbers of patients.
author year No. regimen response 
rate
median survival 
time
1-year survuval 
rate
JL Raoul [13] 1995 24 radiotherapy + chemotherapy 65% - 47.1%
H Yamanaka [25] 1998 17 radiotherapy + CDGP§ + 5-FU# 76.50% - -
K Nemoto [15] 2001 33 radiotherapy alone(21) or radiotherapy + CDDP* + 
5-FU (12)
- 7 months 33%
Y Nishimura [12] 2003 13 radiotherapy + CDDP + 5-FU 72% 9.5 months 28%
H Shimada [14] 2003 76 chemoradiotheray(47), chemotherapy alone(17), 
radiotherapy alone(12)
34% 8 months 31%
K Nemoto [16] 2003 7 radiotherapy + CDGP + 5-FU 100% - 69%
* CDDP: cisplatin, § CDGP: nedaplatin, # 5-FU: 5-fluorouracilBMC Cancer 2006, 6:50 http://www.biomedcentral.com/1471-2407/6/50
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lent. Although it seems natural that chemoradiotherapy is
more effective than radiotherapy or chemotherapy alone
because of their synergistic and/or additive effects, the
high rate of completion of the regimen because of less tox-
icities of CDGP and the high local control rate might have
contributed to the better results in our study than those in
previous studies on chemoradiotherapy. Although we
have no evidence, CDGP or CDGP + 5-FU might have a
greater synergy with radiation than CDDP or CDDP + 5-
FU. However, we also should consider some biases: for
example, the observation period was too short to deter-
mine long-term results, patients with performance status
of 4 were excluded, patients who had hematogenous
metastasis were excluded, all patients had squamous cell
carcinoma by pure chance, high dose radiotherapy could
be performed easily because of the unused adjuvant nor
neoadjuvant therapy in association with initial surgery,
and some of the 16 patients who had relapse again were
treated with second-line salvage chemotherapy (docetaxel
alone, TS-1 alone, or combined with CDDP or CDGP and
docetaxel) after relapse again. The median survival period
of the 16 patients after relapse again was 9.5 months
(95%CI = 2.4–15.6).
However, only 5 of the 30 patients in the present study
had relapse again inside the irradiation field. Irradiated-
field control rates were 86.4% at 1-year and 72% at 3-year.
Eleven of the 30 patients had relapse again in lymph
nodes outside the irradiation field or in distant organs.
There was no significant difference between survival peri-
ods of patients who had relapse again inside the irradi-
ated-field and patients who had no relapse again inside
irradiated-field. However, we believe that the high irradi-
ated-field control rate of this protocol contributed to pro-
longation of survival. Although there was also no
significant difference (median survival time; one region
vs. multiple regions: 39.0 vs. 6.5 months, p = 0.19),
number of recurrent regions also might have no small
effect on survival.
Regarding the optimal irradiation field, we have experi-
enced whether we need to irradiate to three-field includ-
ing the bilateral supraclavicular, mediastinal and celiac
regions or just the recurrent region of recurrence. In the
present study, a T-shaped field was used in 11 patients.
Although there was no significant difference, the median
survival period of patients who received irradiation to the
recurrent region alone was longer than that of patients
who received T-shaped field irradiation (local vs. T-
shaped: 39.0 vs. 14.0 months, p = 0.17; log-rank test). It
was thought that this difference in the median survival
period was due to the fact that a T-shaped field was often
used for patients having multiple regional recurrences,
although there was no significant correlation. Moreover,
the problem of the significantly high rate of adverse events
in patients who were treated with a T-shaped field
remains, although most of these adverse events were con-
trollable. To our knowledge, there is no report about irra-
diation fields for postoperative recurrent esophageal
cancer. Prospective randomized studies on irradiation
fields are needed.
The optimal radiation dose for recurrent esophageal can-
cer had also not been determined. About 60 Gy of radio-
therapy combined with chemotherapy is preferred in
Japan. Since TD5/5 (prediction radiation-dose of normal
tissue complication probability at 5% within 5 years after
radiotherapy) of the stomach is 60 Gy [27] and since one
of our patients died of necrosis of the stomach, which had
been used for thoracic esophageal substitution, 6 months
after the end of 66 Gy radiotherapy, we avoid irradiation
to the gastric tube with a total dose of more than 60 Gy.
We have no major matter of stomach using 60 Gy/30 frac-
tions/6 weeks radiotherapy. But the tolerance radiation-
dose of gastric tube with chemotherapy has not been
known. Although patients with primary esophageal can-
cer in the Intergroup Trial (INT) 0123 (Radiation Therapy
Oncology Group (RTOG) 94-05) study were assigned ran-
domly to receive combined-modality therapy consisting
of CDDP (75 mg/m2 bolus day 1) + 5-FU (1000 mg/m2/
24 hours for 4 days) with concurrent 64.8 Gy of radiother-
apy or the same chemotherapy schedule but with concur-
rent 50.4 Gy of radiotherapy, there was no significant
difference in median survival, 2-year survival, or local/
regional failure and local/regional persistence of disease
[26]. Therefore, at present, four cycles of CDDP + 5-FU
combined with 50 Gy of radiotherapy is a standard chem-
oradiotherapy regimen for advanced esophageal cancer in
U.S.A.. As for primary esophageal cancer, a total dose 50
Gy radiotherapy with concurrent chemotherapy may be
Relapse-free survival and irradiated-field control rates/(Kap- lan-Meier method) Figure 4
Relapse-free survival and irradiated-field control rates/(Kap-
lan-Meier method).BMC Cancer 2006, 6:50 http://www.biomedcentral.com/1471-2407/6/50
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sufficient for recurrent esophageal cancer. It is necessary to
investigate prospectively the optimal radiation dose for
postoperative locoregional recurrent esophageal cancer.
CDGP has shown less renal toxicity but an anti-tumor
effect similar or superior to that of CDDP in some preclin-
ical and clinical studies [20-23]. Although the optimal
doses of CDGP and 5-FU with radiotherapy have not been
determined, we used doses of the anti-tumor drugs in the
present study based the report by Yoshioka et al. [25].
They administered CDGP at a dose of 80 or 100 mg/m2/2
hours and 5-FU at a dose of 350 or 500 mg/m2/24 hours
for 5 days and recommended 100 mg CDGP/m2 and 500
mg 5-FU/m2. In the present study, we decided to adminis-
ter CDGP at a 70% dose of their recommendation with
consideration of concurrent radiotherapy.
The major toxicities are listed in Table 4. About major tox-
icities of this protocol in the acute phase, grade 4 toxicity
was observed in only two patients. Grade 3 or higher tox-
icities of neutropenia, thrombocytopenia and esophagitis
occurred in 30%, 3.3% and 3.3% of the patients, respec-
tively. However, these grade 3 toxicities were temporary or
controllable, and the protocol was performed in 23
patients without suspension or discontinuation and with-
out reduction in the dose of chemotherapy. Therefore, the
rate of completion of this regimen was high (76.7%).
Compared to results of some clinical studies on chemora-
diotherapy, for example, a phase II study by Ohtsu et al.
[28], Japan Clinical Oncology Group Trial (JCOG) 9516
[29], a report by Burmeister et al. [30], RTOG 85-01 [31]
and INT 0123 [26], which cause a standard regimen for
primary esophageal cancer in U.S.A., the rate of grade 4–5
toxicity in this study was low. The chemoradiotherapy
protocol used in this study is therefore feasible and safe.
The results of several studies, including the present study,
indicate that CDGP + 5-FU is no less safe and effective
than CDDP + 5-FU [16,17,24,25]. Extensive prospective
randomized studies are needed to compare the effective-
ness and safety of radiotherapy combined with CDGP + 5-
FU and those of radiotherapy combined with CDDP + 5-
FU.
As prognostic factors of postoperative recurrent esopha-
geal cancer, PS, age (worse for younger patients) and
recurrent pattern (worse for patients with anastomotic
recurrence), which had no correlation with others, were
significantly associated with survival in univariate analysis
in the present study (Table 5). The reason for the poor
prognosis of young patients is not known. Tumors in
younger patients may be aggressive, although there was
no significant correlation between age and the time inter-
val between surgery and relapse in the present study. The
reason for the poor prognosis of patients with anastomic
recurrence might be because of the significant correlation
with PS and pattern of recurrence (p = 0.002, Pearson's
product moment correlation coefficient = -0.539; the
patients with anastomic recurrence were worse PS). We
Table 5: Prognostic factors. Cox's proportional hazards regression model was used for univariate survival analysis.
factor group No. median survival time log-rank univariate
(month) p p
performance status 0–1 25 39 0.018 0.033
2–3 5 8
age ≥65 12 39 0.017 0.034
<65 18 10
preoperative stage (UICC§ 1997) I – II 9 0.87 0.87
III – IV 19 39
number of cycles of chemotherapy 1 5 9 0.50 0.501
22 5 3 9
time interval between surgery and recurrence >13 14 0.083 0.212
≤13 16 14
tumor response (RECIST*) CR-PR 22 39 0.27 0.277
SD-PD 8 12
field local 19 39 0.17 0.183
T-shaped 11 14
relapse again inside irradiated field + 5 0.57 0.594
-2 5 3 9
number of recurrent regions one 23 39 0.19 0.206
multiple 7 6.5
recurrent pattern local 9 6.0 0.015 0.024
non-local 21 39.0
*RECIST: Response Evaluation Criteria in Solid Tumors, §UICC: Union International Contre le Cancer
Three blank columns show that the median survival times could not be calculated.BMC Cancer 2006, 6:50 http://www.biomedcentral.com/1471-2407/6/50
Page 8 of 9
(page number not for citation purposes)
previously reported that the interval between surgery and
relapse was a prognostic factor of recurrent esophageal
cancer [15], but this was not selected as a prognostic factor
in univariate analysis in the present study.
Conclusion
The present protocol of radiotherapy combined with
nedaplatin and 5-fluorouracil is a safe and effective sal-
vage treatment for postoperative locoregional recurrent
esophageal cancer.
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